A simple blood test delivering fibrosis, activity, and steatosis with no indeterminate results.
Chief Medical Officer (CMO), Summit Clinical Research. Director of the Steatotic Liver Program. Clinical Research Institute of Ohio (CRIOH)
LIVERFASt™ is a blood-based noninvasive test. It uses the input from 10 biomarkers and patient anthropometrics to generate and provide results using advanced analytics and a scoring system that has been developed over 10 years of research.
LIVERFASt™ is easy to do. A simple blood draw from a patient is analyzed in Fibronostics’ CAP & CLIA certified laboratory. Results are returned to the prescribing physician via our portal, physician’s EMR or other forms of integration.
Tests Conducted
Countries Sold
LIVERFASt™ is a simple blood test that evaluates your liver health. Backed by over 10 years of research, it uses advanced analytics to combine 10 standard blood markers with your basic physical details (like age and weight) to assess the liver.
LIVERFASt™ is a simple, non-invasive blood test that provides a comprehensive assessment of liver health. It generates scores and biopsy-aligned classifications for liver fibrosis, steatosis (fat accumulation), and MASH activity (inflammation), enabling evaluation of these key liver disease features without the need for a liver biopsy.
LIVERFASt™ is remarkably easy to do. A single, routine blood draw is analyzed in Fibronostics’ CAP & CLIA certified laboratory. Results are seamlessly returned to the prescribing physician via our secure portal, direct to the EMR, or via API integration.
Identify at-risk patients early
Quantify fibrosis, activity, steatosis
Reduce unnecessary FibroScan/biopsy
Track disease progression/treatment response
Find more and miss less patients
Precisely identify and stage at-risk patients
Track patients and treatments dynamically
Optimizes triage and referral pathways
The poster presents a retrospective study on the use of non-invasive tests (NITs) to initiate and monitor Resmetirom
This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing
Evaluates the accuracy of LiverFast, a non-invasive blood test, in determining the severity of liver scarring (fibrosis) in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
